EndoTheia completes first-in-human study of steerable kidney stone basket

EndoTheia completed the first-in-human clinical trial for its FlexStone basket, a steerable kidney stone treatment. Nashville, Tennessee-based EndoTheia said its FlexStone basket represents the...

Second Heart Assist’s Whisper device has successful case studies

Second Heart Assist announced successful case studies in South America with its Whisper catheter-delivered heart assist device. Dr. Adrian Ebner, head of the cardiovascular...

Tivic completes enrolment in nerve stim trial

Tivic Health Systems completed enrollment in a study for its vagus nerve stimulation (VNS) device. The study, conducted by The Feinstein Institute of Bioelectronic Medicine,...

Aethlon Medical enrols first patient in trial of Hemopurifier device for cancer

Aethlon Medical has enroled the first patient in its Australian clinical trial evaluating the safety, feasibility, and optimal dosing of the Hemopurifier device in...

Vivasure sees success in absorbable large-bore vessel device trial

Irish absorbable tech company, Vivasure Medical, has announced results from a US Investigational Device Exemption (IDE) PATCH pivotal trial finding that its fully absorbable...

CytexOrtho gets FDA approval for first-in-human trial of absorbable hip implants

CytexOrtho today said it has approval from the FDA to start a Phase 1 clinical trial evaluating the safety and efficacy of its absorbable...

Positive data for Cardiawave’s ultrasound tech that treats calcified aortic stenosis

Cardiawave said its device for the treatment of severe symptomatic calcific aortic stenosis (CAS) met the primary endpoint in a pivotal study. The investigational...

Sonablate enrols first patient in incompetent vein ablation clinical trial

Sonablate announced the first patient enrolment in its HIFIVE U.S. clinical trial, which is testing high-intensity focused ultrasound (HIFU) for the noninvasive treatment of...

BlueWind Medical reports positive data for tibial neuromod

BlueWind Medical shared two-year data from the OASIS pivotal study of its implantable tibial neuromodulation (iTNM) system. Park City, Utah-based BlueWind said investigators presented...

Latest articles